Reverse-phase protein microarrays for tissue-based analysis

Current Opinion in Molecular Therapeutics

Volumn 7, Issue 3, 2005, Pages 240-245

  Speer, Runa ^a   Wulfkuhle, Julia D ^a   Liotta, Lance A ^a   Petricoin III, Emanuel F ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b GEORGE MASON UNIVERSITY   (United States)

Author keywords

Microarrays; Protein proteomics; Reverse phase; Tailored therapy

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; IMATINIB; ISIS 3521; MESSENGER RNA; PEROXIDASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN TYROSINE KINASE; STREPTAVIDIN; SYNAPTOPHYSIN;

BIOINFORMATICS; BIOTECHNOLOGY; CLINICAL TRIAL; COMPUTER PROGRAM; CYTOLYSIS; GENE STRUCTURE; GENETIC ANALYSIS; GENOMICS; HUMAN; HUMAN GENOME; MICROENVIRONMENT; OVARY CANCER; PATHOGENESIS; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION; STANDARDIZATION; TISSUE MICROARRAY;

ANIMALS; HUMANS; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; TISSUE ARRAY ANALYSIS;

EID: 20344386941     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA: Clinical proteomics: Translating benchside promise into bedside reality. Nat Rev Drug Discov (2002) 1(9):683-695.
2. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, Gillespie JW, Emmert-Buck MR, Roth MJ, Petricoin EF 3rd, Liotta LA: Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene (2001) 20(16):1981-1989.
3. Espina V, Mehta AI, Winters ME, Calvert V, Wulfkuhle J, Petricoin EF 3rd, Liotta LA: Protein microarrays: Molecular profiling technologies for clinical specimens. Proteomics (2003) 3(11):2091-2100.
4. Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF 3rd, Liotta L: Proteomic approaches to the diagnosis, treatment, and monitoring of cancer. Adv Exp Med Biol (2003) 532:59-68.
5. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med (1998) 4(7):844-847.
6. Knezevic V, Leethanakul C, Bichsel VE, Worth JM, Prabhu VV, Gutkind JS, Liotta LA, Munson PJ, Petricoin EF 3rd, Krizman DB: Proteomic profiling of the cancer microenvironment by antibody arrays. Proteomics (2001) 1(10):1271-1278.
7. MacBeath G, Schreiber SL: Printing proteins as Microarrays for high-throughput function determination. Science (2000) 289(5485):1760-1763.
8. Lueking A, Horn M, Eickhoff H, Bussow K, Lehrach H, Walter G: Protein microarrays for gene expression and antibody screening. Anal Biochem (1999) 270(1):103-111.
9. Arenkov P, Kukhtin A, Gemmell A, Voloshchuk S, Chupeeva V, Mirzabekov A: Protein microchips: Use for immunoassay and enzymatic reactions. Anal Biochem (2000) 278(2):123-131.
10. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G: Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol (2001) 159(6):2249-2256.
11. Greenbaum D, Baruch A, Hayrapetian L, Darula Z, Burlingame A, Medzihradszky KF, Bogyo M: Chemical approaches for functionally probing the proteome. Mol Cell Proteomics (2002) 1(1):60-68.
12. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature (2001) 411(6835):355-365.
13. Celis JE, Gromov P: Proteomics in translational cancer research: Toward an integrated approach. Cancer Cell (2003) 3(1):9-15.
14. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, Weiss RA, Liotta LA: Laser capture microdissection. Science (1996) 274(5289):998-1001.
15. Clinical Proteomics Program. National Cancer Institute, Bethseda, MD, USA (2005). http://home.ccr.cancer.gov/ncifdaproteomics/.
16. Liotta LA, Kohn EC, Petricoin EF: Clinical proteomics: Personalized molecular medicine. J Am Med Assoc (2001) 286(18):2211-2214.
17. Emmert-Buck MR, Gillespie JW, Paweletz CP, Ornstein DK, Basrur V, Appella E, Wang QH, Huang J, Hu N, Taylor P, Petricoin EF 3rd: An approach to proteomic analysis of human tumors. Mol Carcinog (2000) 27(3):158-165.
18. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell (2000) 100(1):57-70.
19. Liotta LA, Kohn EC: The microenvironment of the tumour-host interface. Nature (2001) 411(6835):375-379.
20. Chadwood J, Bryant D, Skehel JM, Camilleri P: Analysis of N-linked oligosaccharides: Progress towards the characterisation of glycoprotein-linked carbohydrates. Biomol Eng (2001) 18(5):229-240.
21. Oda Y, Nagasu T, Chait BT: Enrichment analysis of phosphorylated proteins as a tool for probing the phosphoproteome. Nat Biotechnol (2001) 19(4):379-382.
22. Ducret A, Desponts C, Desmarais S, Greaser MJ, Ramachandran C: A general method for the rapid characterization of tyrosine-phosphorylated proteins by mini two-dimensional gel electrophoresis. Electrophoresis (2000) 21(11):2196-2208.
23. Liotta L, Petricoin E: Molecular profiling of human cancer. Nat Rev Genet (2000) 1(1):48-56.
24. Chambers G, Lawrie L, Cash P, Murray GI: Proteomics: A new approach to the study of disease. J Pathol (2000) 192(3):280-288.
25. Rudert F: Genomics and proteomics tools for the clinic. Curr Opin Mol Ther (2000) 2(6):633-642.
26. Nishizuka S, Chen ST, Gwadry FG, Alexander J, Major SM, Scherf U, Reinhold WC, Waltham M, Charboneau L, Young L, Bussey KJ et al: Diagnostic markers that distinguish colon and ovarian adenocarcinomas: Identification by genomic, proteomic, and tissue array profiling. Cancer Res (2003) 63(17):5243-5250.
27. Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF 3rd: Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 3(11):2085-2090.
28. Zha H, Raffeld M, Charboneau L, Pittaluga S, Kwak LW, Petricoin E 3rd, Liotta LA, Jaffe ES: Similarities of prosurvival signals in Bcl-2-positive and Bcl-2-negative follicular lymphomas identified by reverse phase protein microarray. Lab Invest (2004) 84(2):235-244.
29. Grubb RL, Calvert VS, Wulkuhle JD, Paweletz CP, Linehan WM, Phillips JL, Chuaqui R, Valasco A, Gillespie J, Emmert-Buck M, Liotta LA, Petricoin EF: Signal pathway profiling of prostate cancer using reverse phase protein arrays. Proteomics (2003) 3(11):2142-2146.
30. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2002) 8(8):2530-2535.
31. Sheehan KM, Calvert VS, Kay EW, Liu Y, Fishman D, Espina V, Aquino J, Speer R, Araujo R, Mills GB, Liotta LA et al: Use of reverse phase protein microarrays and reference standard development for molecular network analysis of metastatic ovarian carcinoma. Mol Cell Proteomics (2005) 4(4):346-355.
32. Rosenblatt KP, Bryant-Greenwood P, Killian JK, Mehta A, Geho D, Espina V, Petricoin EF 3rd, Liotta LA: Serum proteomics in cancer diagnosis and management. Annu Rev Med (2004) 55:97-112.
33. Leyland-Jones B: Trastuzumab: Hopes and realities. Lancet Oncol (2002) 3(3):137-144.
34. Keen N, Taylor S: Aurora-kinase inhibitors as anticancer agents. Nat Rev Cancer (2004) 4(12):927-936.
35. Santen RJ, Song RX, McPherson R, Kumar R, Adam L, Jeng MH, Yue W: The role of mitogen-activated protein (MAP) kinase in breast cancer. J Steroid Biochem Mol Biol (2002) 80(2):239-256.
36. Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature (2001) 411(6835):342-348.
37. Moasser MM, Basso A, Averbuch SD, Rosen N: The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res (2001) 61(19):7184-7188.
38. Normanno N, Campiglio M, De LA, Somenzi G, Maiello M, Ciardiello F, Gianni L, Salomon DS, Menard S: Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann Oncol (2002) 13(1):65-72.
39. Zwick E, Bange J, Ullrich A: Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol Med (2002) 8(1):17-23.
40. Traxler P, Bold G, Buchdunger E, Caravatti G, Furet P, Manley P, O'Reilly T, Wood J, Zimmermann J: Tyrosine kinase inhibitors: From rational design to clinical trials. Med Res Rev (2001) 21(6):499-512.